Cargando…
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease
BACKGROUND: Multiple preclinical studies have highlighted AMP-activated protein kinase (AMPK) as a potential therapeutic target for autosomal dominant polycystic kidney disease (ADPKD). Both metformin and canagliflozin indirectly activate AMPK by inhibiting mitochondrial function, while salsalate is...
Autores principales: | Leonhard, Wouter N., Song, Xuewen, Kanhai, Anish A., Iliuta, Ioan-Andrei, Bozovic, Andrea, Steinberg, Gregory R., Peters, Dorien J.M., Pei, York |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796518/ https://www.ncbi.nlm.nih.gov/pubmed/31473186 http://dx.doi.org/10.1016/j.ebiom.2019.08.041 |
Ejemplares similares
-
Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease
por: Kanhai, Anish A., et al.
Publicado: (2023) -
Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model
por: Song, Xuewen, et al.
Publicado: (2023) -
Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease
por: Iliuta, Ioan-Andrei, et al.
Publicado: (2022) -
Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation
por: Shi, Beili, et al.
Publicado: (2019) -
Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease
por: Oto, Ozgur A., et al.
Publicado: (2023)